• Produto
    • Produto
    • Fornecedor

New Anti-drooling Drug of Taiwan’s Orient Europharma Approved for More Testing

Source: Taiwantrade | Updated: 16 March 2011

Taiwan’s Orient Europharma Co. Ltd. is currently developing a new anti-drooling drug, and the new drug has already obtained approval from the US Food and Drug Administration to continue with the second phase clinical testing. This new drug mainly treats the excessive drooling of Parkinson’s disease patients. At the moment, about 4 million people in the world have Parkinson’s disease and their total medical cost is as high as US$2.8 billion. Hence, when Orient Europharma’s new anti-drooling drug is on the market, the revenue it can generate should be significant.

Orient Europharma has pointed out that besides Parkinson’s disease, the new anti-drooling drug can also be used to treat other illnesses that can cause excessive drooling, such as cerebral palsy, esophageal cancer, stroke, and Duchenne muscular dystrophy (DMD).

Please click here for pharmaceutical products on Taiwantrade.

HemiDemi funP推推王 Baidu Google Bookmarks Yahoo! My Web PChome HemiDemi funP推推王 Baidu Google Bookmarks Yahoo! My Web PChome Del.icio.us Digg technorati furl UDN More bookmarks, 其他更多書籤


Loading ...

Recomendação para Pequenas Quantidades

Loading ...